Transforming stem cell transplant
therapy for auto-immune and blood-
based diseases (NASDAQ: MGTA)

Targeting the DNA damage
response pathway to prevent and
halt expansion repeat disorders

Pioneering targeted
therapies for serious
muscle diseases

Advancing targeted protein
degradation to target previously
“undruggable” disease pathways

Novel medicines for auto-
immune diseases – Sold to
BMS (NYSE:BMY) Mar 2016

New class of
regulated cell and
gene therapies

Novel antibodies built to break
through the tumor microenvironment
IPO Apr 2018 (NASDAQ: SURF)

Enhancing synaptic integrity for
treatment of neurologic dis-
orders; sold to Alkermes Nov 2019

Genomics-based cancer
drug discovery – IPO
Apr 2000 (NASDAQ: EXEL)

Cell and gene therapies
for rare diseases
IPO Jun 2018 (NASDAQ: AVRO)

Restoring metabolic balance to treat
NASH and serious metabolic diseases
– IPO Jun 2019 (NADSAQ: AKRO)

Developing treatments for
complex rare diseases
(NASDAQ: LRMR)

Novel biologic therapeutics for
autoimmune diseases – Sold to
Celgene (NASDAQ: CELG) Jan 2017

Novel antibiotics –
Sold to AstraZeneca
(NYSE: AZN) Mar 2010

RNAi-based drugs for
severe diseases – IPO
Jun 2004 (NASDAQ: ALNY)

Novel therapies for severe, highly
drug-resistant bacterial infections
IPO Nov 2017 (NASDAQ: SPRO)

Genetic analysis to find novel
drug targets – Sold to Amgen
(NASDAQ: AMGN) Dec 2012

Preventing axonal degeneration
in patients with
neurological diseases

Covalent irreversible
inhibitors – Sold to Celgene
(NASDAQ: CELG) Jan 2012

Designing Synthetic Biotic
living medicines to treat disease
(NASDAQ: SYBX)

Developing medicines
that target inflammation
at its core

Unlocking nature’s regulatory
mechanisms to fuel the
discovery of new medicines

Proprietary pharmaceuticals for
neonatal care and pediatrics –
Sold to Mallinckrodt Aug 2017

Targeting RNA-modifying
proteins for novel
precision cancer therapies

Bispecific antibodies
to improve the treatment
of serious diseases

Mouse platforms for the generation
of fully human antibodies –
Sold to Harbour BioMed Dec 2016

Re-dosable, titratable genetic
medicines with drug-like properties
for patients with genetic diseases

Development of complex
biopharma products – IPO
Jun 2004 (NASDAQ: MNTA)

Harnessing the immune system
to defeat cancer with
tumor-selective immunotherapies

First-in-class
RNA therapies
for severe genetic diseases

Novel bicyclic peptides (bicycles) and
bicycle drug conjugates for cancer
IPO May 2019 (NASDAQ: BCYC)

Novel vaccine platform –
Sold to Johnson & Johnson
(NYSE: JNJ) Oct 2010

Novel therapeutics using proprietary
computational chemistry –
Sold to Allergan (NYSE: AGN) Sep 2016

Human antibody therapies for
oncology – Sold to Daiichi
Sankyo (TYO: 4568) May 2008

Rapidly developing new
cancer treatments for
people of all ages

Universal cell-based
cancer immunotherapy
IPO Mar 2018 (NASDAQ: UMRX)

Building
the future of
gene therapy

Novel cancer drugs using
combinatorial chemistry –
IPO Oct 1996 (NASDAQ: ARQL)

Applying new insights in
hepcidin biology to
treat hematologic diseases

Therapies for severe
cardiovascular diseases –
IPO Apr 2000 (SWX: ATLN)

Novel fibrosis therapeutic –
Sold to Biogen Idec
(NASDAQ: BIIB) Feb 2012

Novel bio-therapies –
Sold to Bristol-Myers Squibb
(NYSE: BMY) Oct 2007

Discovering and developing
novel integrin antagonists for
serious fibrotic diseases

Targeting progranulin and
lysosomal biology to treat
neurodegenerative diseases

Targeting regulators of
innate and adaptive immunity
to restore immune homeostasis

World-class antibody
discovery platform – IPO
Mar 1999 (XETRA: MOR.DE)

Translating natural
RNA editing into new
possibilities for patients

Creating breakthrough
therapies for neurological
and psychiatric conditions

Innovative micro-RNA-
based therapies –
IPO Feb 2017 (NASDAQ: MGEN)

Patient-directed oncology
therapies across immune and
cancer cell pathways

Cancer therapeutics and
diagnostics – Sold to Amgen
(NASDAQ: AMGN) Jan 2012

Anti-viral therapies –
Sold to AstraZeneca
(NYSE: AZN) Feb 2007

Novel anesthetics –
Sold to The Medicines Company
(NASDAQ: MDCO) Jan 2015

Novel antibodies for immuno-
oncology – Sold to Novartis
(NYSE: NVS) Feb 2014

Novel therapeutics
targeting
diseases of aging

Breakthrough computer-aided
drug design
for transformative medicines

Precision therapeutics for
genetically-defined age-related
macular degeneration and rare diseases

Utilizing the innate immune
system to treat cancer and
inflammatory diseases

Discovering new medicines
for severe
neurodegenerative diseases

Next-generation oncolytic immuno-
therapies for cancer treatment
– IPO Jul 2018 (NASDAQ: REPL)

Migraine prevention therapy –
Sold to Eli Lilly (NYSE: LLY)
Dec 2013

Precision gene editing to
cure severe diseases –
IPO May 2016 (NASDAQ: NTLA)